While Dogecoin (DOGE) is dominating headlines with 200% rally hopes based on whale purchasing and ETF hysteria, emerging altcoin Mutuum Finance (MUTM) is emerging as the superior 2025 purchase. Currently at $0.035, MUTM has already garnered more than $16.5 million in its presale and has had more than 16,620 holders, increasing market belief.  Unlike DOGE, […]While Dogecoin (DOGE) is dominating headlines with 200% rally hopes based on whale purchasing and ETF hysteria, emerging altcoin Mutuum Finance (MUTM) is emerging as the superior 2025 purchase. Currently at $0.035, MUTM has already garnered more than $16.5 million in its presale and has had more than 16,620 holders, increasing market belief.  Unlike DOGE, […]

Dogecoin (DOGE) Could Surge 200% Beyond Its ATH Amid Whale Accumulation and ETF Buzz, But this $0.035 Token Remains the Better Buy in 2025

2025/09/29 02:30
4 min read

While Dogecoin (DOGE) is dominating headlines with 200% rally hopes based on whale purchasing and ETF hysteria, emerging altcoin Mutuum Finance (MUTM) is emerging as the superior 2025 purchase. Currently at $0.035, MUTM has already garnered more than $16.5 million in its presale and has had more than 16,620 holders, increasing market belief. 

Unlike DOGE, founded on hype and speculation trading, Mutuum Finance offers genuine DeFi applications in its lending and borrowing process, robust security measures, and staking rewards. MUTM is a high-performing token with immense growth opportunities and turning it into a viable contender for those who seek real value and appreciation in the future.

Dogecoin’s Next Big Moment?

Dogecoin (DOGE) is once more making enormous waves as experts are calling for almost 200% more in the near future. The reason behind the optimism is top-tier whale accumulation and rising hope that a DOGE ETF with a 99% probability of listing is on its way. 

Such an event will most likely put DOGE back in the limelight, having the potential to push it above its last all-time high and reviving mainstream interest. Investors are wondering if this is the catalyst that secures DOGE’s long-term value, or just another hype-driven spike. For most investors, that is precisely why growing interest is being shifted to newer player, Mutuum Finance (MUTM).

Mutuum Finance Reports Strong Presale Momentum

Mutuum Finance (MUTM) continues to experience strong momentum as it enters Phase 6 of its presale, gaining over 16,620 investors and raising over $16.5 million. Increasing entry is evidence of growing faith in the project’s long-term future and vision for the decentralized finance future.

As part of its commitment to its values of transparency and security, Mutuum Finance has partnered with CertiK to launch a $50,000 Bug Bounty Program. The program enables security researchers and developers to scan for platform vulnerabilities at four severity levels, namely critical, major, minor, and low. The program is just one of the several that Mutuum is taking to become even more secure on its infrastructure and earn the trust of its burgeoning community.

Dynamic Interest Rates and Maximum Efficiency

In the center of the Mutuum Finance protocol is an computerized real-time floating interest rate system that adjusts according to liquidity levels. Under periods of high liquidity, the cost of borrowing goes down, which stimulates lending and capital flowing in. Under periods of low liquidity, borrowing cost goes up to stimulate loan repayments and new deposits. The self-balancing mechanism achieves a natural equilibrium, reducing the potential for over-leveraging and overall ecosystem health.

Efficiency is also maintained with collateral optimization, particularly when co-related assets are utilized. Collateralized positions entered into in a secure manner command more borrowing capacity with improved Loan-to-Value (LTV) terms, and reserve factors act as buffers during periods of market fluctuations. Volatile assets have greater reserve requirements to maintain low uncertainty, but stable low-volatility assets can have increased borrowing with minimal liquidation risk. LTV ratios and liquidation points are constantly updated to reflect each token it lists’ distinctive volatility profiles, evenly distributing risk throughout the platform. 

With its presale success, ground-breaking risk management technology, and solid commitment to security and transparency, Mutuum Finance (MUTM) is becoming a robust and resilient network well-positioned for long-term adoption, expansion, and prosperity in the DeFi market. 

Hype vs Utility

Dogecoin’s potential 200% rise is exciting, but its climb remains founded on guesswork and hype. Mutuum Finance, with a value of $0.035, has already raised over $16.5 million and gained over 16,620 investors, reflecting strong market trust. With real DeFi utility, complex risk management, and a real way to long-term success, MUTM is the investment to take. Get involved in the presale of Mutuum Finance now and secure your place before the next significant price shift.

For more information regarding Mutuum Finance (MUTM) please use the following links:

Website: https://mutuum.com/

Linktree: https://linktr.ee/mutuumfinance

Market Opportunity
DOGE Logo
DOGE Price(DOGE)
$0.09355
$0.09355$0.09355
-1.74%
USD
DOGE (DOGE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26